A clinician wants to assess whether a new lipid lowering drug (Fluvastatin) affects levels of low-density lipoprotein (LDL, in mmol/L) among 900 participants. In the clinical trial, a total of 443 participants were randomised to receive the treatment (Eluvastatin) and another 457 to receive a placebo (no treatment). Participants were then followed up over a period of 12 weeks and LDL levels were then measured. The research question is "does Fluvastatin treatment affect LDL levels?" The table and figure below provide descriptive statistics of the LDL levels (in mmol/L) according to the placebo and treatment groups. LDL (mmol/L) LDL (mmol/L) 6.0 5.0 ; 30 20 Fluvastatin Placebo N 443 457 Mean Std. deviation 3.54 4.03 307 0.76 0.85